Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas Gains Worldwide Rights to Next-Gen DNA Vaccines
October 13, 2015
- (PRESS RELEASE) Shionogi to Spin Off Consumer Healthcare Biz Next Year
October 13, 2015
- Eisai’s Thyroid Cancer Drug Lenvima Approved in S. Korea
October 13, 2015
- AZ Begins Japan PI Trial of CTLA-4 Inhibitor for Malignant Mesothelioma
October 9, 2015
- Ethical Drug Sales Surge 9.0% in August: Crecon Report
October 8, 2015
- Meiji Seika Pharma Commences Long-Term Studies of Safinamide
October 8, 2015
- Merck Lauds Nobel Medicine Prize Winners Omura, Campbell
October 7, 2015
- GreenPeptide Files IND in US for Cancer Peptide Vaccine
October 7, 2015
- Anti-Obesity Effect of Rare Sugar D-Psicose Confirmed: Matsutani Chemical Industry
October 7, 2015
- Eisai Offers Indonesia 151 Million Tablets of Elephantiasis Drug for Free
October 6, 2015
- GSK to Seek COPD Indication for Relvar in January-March 2016
October 6, 2015
- Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
- Japan OTC Drug Market Logs 1st Rise in 5 Years: Fuji Keizai
October 5, 2015
- Mitsubishi Tanabe Wins Rights to Regeneron’s NGF Antibody in Asia
October 5, 2015
- Otsuka Files Combination Glaucoma Eye Drops in Japan
October 2, 2015
- ASKA Takes Over 2 Anti-Thyroid Drugs from Chugai
October 2, 2015
- Active Promotion of HPV Vaccines Should Be Resumed: GSK
October 1, 2015
- Mitsubishi Tanabe Raises Full-Year Earnings Projection
October 1, 2015
- Nichi-Iko Files Remicade Biosimilar in Japan
October 1, 2015
- Sato, POLA to Jointly Market Clenafin Competitor Drug
October 1, 2015
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…